This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1

This study has been completed.
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: July 26, 2005
Last updated: January 11, 2017
Last verified: August 2007
Schizophrenic individuals are typically nicotine dependent smokers who find it difficult to quit smoking. The purpose of this study is to determine the effectiveness of bupropion SR (commonly known as Zyban) in combination with a nicotine transdermal patch (NTP), in helping schizophrenic individuals quit smoking. In addition, this study will evaluate how the combination of bupropion SR and NTP affects psychiatric symptoms and medication side effects.

Condition Intervention Phase
Tobacco Use Cessation Tobacco Use Disorder Schizophrenia Drug: Bupropion Drug: nicotine transdermal patch Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Optimizing Treatment for Schizophrenic Smokers

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • 7 day point prevalence of cigarette abstinence [ Time Frame: End of trial (week 10) ]

Secondary Outcome Measures:
  • Craving [ Time Frame: assessed weekly ]
  • Medication compliance [ Time Frame: assessed weekly ]
  • Depression [ Time Frame: assessed at weeks 1, 4, 7, 10 and at six-month followup ]
  • Withdrawal symptoms [ Time Frame: assessed weekly and at six month followup ]
  • Schizophrenic symptoms [ Time Frame: assessed at weeks 1, 4, 7, 10 and at six-month followup ]

Enrollment: 59
Study Start Date: September 2001
Study Completion Date: May 2007
Arms Assigned Interventions
Experimental: 1
Nicotine Patch + Bupropion
Drug: Bupropion Drug: nicotine transdermal patch
Placebo Comparator: 2
Nicotine patch + placebo
Drug: nicotine transdermal patch

Detailed Description:

Past research on the use of the NTP, atypical antipsychotics, and bupropion in schizophrenic individuals to aid in smoking cessation has been encouraging. The purpose of this study is to compare bupropion SR to a placebo to determine its effectiveness when used in combination with an NTP to help schizophrenic individuals quit smoking.

Participants in this double-blind, placebo-controlled study will be randomly assigned to receive either the NTP (21 mg/day) and placebo or the NTP and bupropion SR (300 mg/day). Participants will begin taking one pill each day of bupropion SR (150 mg/day) or placebo at the start of the second week of the study. After three days, the dose of bupropion SR or placebo will increase to 2 pills each day. Participants will continue this dosing regimen until the end of Week 10. Throughout the 10-week study, participants will receive weekly group therapy.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • DSM-IV diagnosis of schizophrenia or schizoaffective disorder and nicotine dependence
  • Fagerstrom Test for Nicotine Dependence (FTND) score greater than 5
  • Smokes at least 20 cigarettes per day (1 pack per day)
  • Expired breath CO level > 10 ppm and cotinine level > 210 ng/ml at the baseline measurement
  • Currently taking a stable dose of antipsychotic
  • Complete remission from positive symptoms of psychosis as judged by a psychiatric evaluation

Exclusion Criteria:

  • Meets criteria for current abuse or dependence for any alcohol or illicit substance within the past month
  • History of hypersensitivity to bupropion or the nicotine transdermal patch (NTP)
  • Current diagnosis of a serious documented medical disorder that would make bupropion treatment risky OR results of psychiatric/medical screening that suggest a reason for concern (e.g., a history of severe heart, liver, or kidney disease or diabetes mellitus)
  • Currently taking monoamine oxidase inhibitors or bupropion (Zyban or Wellbutrin)
  • Currently taking diabetes mellitus medications, St. John's Wort, appetite suppressants, ephedrine-containing medications, theophylline, clonidine, reserpine, methyldopa, or anti-anginal medications (e.g., beta-blockers, calcium channel blockers, nitroglycerin preparations)
  • History of schizoaffective disorder and not stabilized on a mood stabilizer (e.g., lithium, valproate, carbamazepine)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00124683

Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Tony P George, M.D. Yale University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00124683     History of Changes
Other Study ID Numbers: NIDA-13672-1
Study First Received: July 26, 2005
Last Updated: January 11, 2017

Keywords provided by National Institute on Drug Abuse (NIDA):
nicotine dependence

Additional relevant MeSH terms:
Tobacco Use Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors processed this record on August 21, 2017